The FDA reclassified 14 peptides: what it means

In early 2025, the FDA finalized a decision that upended peptide therapy in the US: 14 peptides were removed from the agency's bulk drug substances list, cutting off their availability through compounding pharmacies. Thousands of patients who relied on these compounds for recovery, immune support, and other therapeutic uses lost access overnight. Here's what happened, which peptides are affected, and what options remain.

What the FDA actually did

To understand the reclassification, you need a bit of background. Under section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare medications using "bulk drug substances" that appear on specific FDA lists. These peptides don't need individual FDA approval to be compounded; they just need to be on the list.

In 2024, the FDA began reviewing peptides on its bulk drug substances nomination list. After a public comment period and evaluation by the Pharmacy Compounding Advisory Committee (PCAC), the agency determined that 14 peptides did not meet the criteria for continued inclusion. The reasons: insufficient safety data from human clinical trials, concerns about impurities in compounded formulations, and the availability of FDA-approved alternatives for some of the same therapeutic targets.

By March 2025, those peptides were formally removed. Compounding pharmacies that continued to prepare them would be operating outside of FDA compliance.

The 14 peptides affected

The full list of peptides the FDA removed from compounding eligibility:

Why the FDA says it made this move

The FDA's stated rationale centers on patient safety. Most of these peptides have never completed full human clinical trials. BPC-157, for example, has an impressive body of animal research (hundreds of studies showing wound healing, gut protection, and anti-inflammatory effects) but no published Phase II or Phase III human trial data. The FDA's position is straightforward: without that data, the agency can't verify that compounded versions are safe and effective.

There are also manufacturing concerns. Peptides are complex molecules. When compounding pharmacies synthesize or reconstitute them, there's variability in purity, potency, and sterility that doesn't exist with FDA-approved manufacturing. The agency pointed to adverse event reports and inspections of compounding facilities as supporting evidence.

The FDA also noted that for some therapeutic goals, particularly growth hormone deficiency, FDA-approved alternatives already exist.

Why patients and clinicians are frustrated

The frustration is just as easy to understand: these peptides were helping people, and now those people have lost access with no transition plan.

Take Thymosin Alpha-1. It's approved in over 30 countries outside the US under the brand name Zadaxin for hepatitis B and as an immune adjuvant. It has decades of published clinical data. The fact that it lacks FDA approval in the United States doesn't mean it lacks evidence. It means no pharmaceutical company has invested in the US approval process, which can cost hundreds of millions of dollars. For patients with chronic infections or immune deficiencies who were responding well to thymosin alpha-1, this reclassification pulled a tool their doctors considered effective.

The growth hormone secretagogue category is another sore point. Peptides like CJC-1295, Ipamorelin, and Sermorelin were widely prescribed by anti-aging and integrative medicine clinicians. FDA-approved growth hormone (somatropin) exists, but it's significantly more expensive and carries its own side effect profile. Many patients chose secretagogues specifically because they stimulate the body's own GH production rather than replacing it directly.

Several physician groups and compounding pharmacy organizations filed legal challenges. The Outsourcing Facilities Association and the Alliance for Pharmacy Compounding both pushed back, arguing that the FDA's evaluation process didn't adequately weigh the clinical experience accumulated over years of supervised patient use.

What this means if you were using one of these peptides

If you were receiving any of these peptides through a licensed compounding pharmacy, your pharmacy is required to stop producing them. Here's what to consider:

Talk to your prescriber first. Do not abruptly discontinue any therapy without medical guidance. Some of these peptides, particularly the growth hormone secretagogues, may require a tapering strategy, and your provider may have alternatives in mind.

FDA-approved alternatives exist for some use cases. For growth hormone support, prescription somatropin (Genotropin, Norditropin, etc.) remains available, though at higher cost. For immune modulation, your provider may consider other approaches depending on your specific condition. MK-677 (ibutamoren), an oral growth hormone secretagogue, is not a peptide and was not part of this reclassification, though its legal status for human use is its own complicated question.

Some peptides may still be available in other forms. GHK-Cu, for instance, is widely available in topical skincare formulations. The FDA's action specifically targets injectable compounded preparations. Topical copper peptide products sold as cosmetics are a different regulatory category.

Clinical trials may open new doors. One possible outcome of the reclassification is that it forces the issue on formal clinical research. If pharmaceutical companies or research institutions see enough demand, some of these peptides could enter the FDA approval pipeline. BPC-157 in particular has been discussed as a candidate for formal trials given the breadth of its preclinical data.

Where this is heading

This reclassification fits a broader FDA pattern of tightening oversight of compounding pharmacies. The same thing happened with compounded semaglutide and tirzepatide. Once the GLP-1 shortage ended, compounding pharmacies lost the legal basis to produce copies of those drugs, triggering lawsuits and patient disruption.

The tension here is real. The FDA has a legitimate mandate to protect patients from unproven or poorly manufactured drugs. Patients and clinicians have legitimate experience using these peptides therapeutically under medical supervision. The US regulatory framework doesn't have a good middle ground for compounds that have meaningful evidence but haven't gone through the full (and enormously expensive) FDA approval process. Until that changes, expect more fights like this one.

If you're currently using or considering peptide therapy, working with a knowledgeable provider who stays current on the regulatory situation is worth the effort.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Regulatory situations evolve. Verify current FDA guidance before making treatment decisions. Always consult with a qualified healthcare provider before starting, stopping, or changing any peptide therapy.

Sources

1. FDA Final Rule on Bulk Drug Substances for Compounding: Removal of Certain Peptides from the Category 1 List. fda.gov (2025).
2. FDA Pharmacy Compounding Advisory Committee (PCAC) Meeting Materials, 2024. fda.gov.
3. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. Frontiers in Pharmacology. 2024.
4. Garaci E, et al. Thymosin alpha 1: from bench to bedside. Annals of the New York Academy of Sciences. 2007;1112:225-232.
5. FDA Drug Shortages Database: Semaglutide and Tirzepatide Listings. accessdata.fda.gov.
6. Alliance for Pharmacy Compounding Public Comments on FDA Peptide Reclassification. a4pc.org (2024).
7. Outsourcing Facilities Association v. FDA: Legal Challenges to Peptide Removal. Court filings, 2025.
8. Jelenić N, et al. Pentadecapeptide BPC 157: a review. Pharmaceuticals. 2025;18(4):451.